🔗 Visit the ClinicalTrials.gov page for NCT02032745
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | JAMA | 2011 | 4.63 |
| 2 | Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. | Clin Cancer Res | 2007 | 0.95 |